Thyrocare Technologies Ltd
THYROCAREThyrocare Technologies Ltd
THYROCARE
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 60.32 | 9.60 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.09 | 6.40 | 0.53% |
Forecast & Ratings
Detailed Forecast from 2 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Thyrocare Technologies Limited is a diagnostic chain company which offers a range of medical diagnostic tests and profiles of tests that center on early detection and management of disorders and diseases.
Investor Presentation
View olderPeers
Compare with peersApollo Hospitals Enterprise Ltd
Max Healthcare Institute Ltd
Fortis Healthcare Ltd
Global Health Ltd
Narayana Hrudayalaya Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ cr.
All values in ₹ cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 247.51 | 316.63 | 379.32 | 413.52 | 441.44 | 507.05 | 618.11 | 536.27 | 581.64 | 635.83 | ||||||||||
Raw Materials | 69.68 | 81.78 | 94.61 | 110.79 | 117.17 | 163.86 | 170.57 | 163.03 | 166.98 | 467.79 | ||||||||||
| Power & Fuel Cost | 5.32 | 6.35 | 6.68 | 7.77 | 8.69 | 7.64 | 8.40 | 10.70 | 10.15 | |||||||||||
| Employee Cost | 25.70 | 32.00 | 35.34 | 43.35 | 48.92 | 58.07 | 61.13 | 106.15 | 107.86 | |||||||||||
| Selling & Administrative Expenses | 28.89 | 46.14 | 49.57 | 59.27 | 44.48 | 42.16 | 45.47 | 52.69 | 73.23 | |||||||||||
| Operating & Other expenses | 17.33 | 50.17 | 27.59 | 27.50 | 48.01 | 51.70 | 67.74 | 71.57 | 74.90 | |||||||||||
EBITDA | 100.59 | 100.19 | 165.53 | 164.84 | 174.17 | 183.62 | 264.80 | 132.13 | 148.52 | 168.04 | ||||||||||
| Depreciation/Amortization | 18.24 | 18.05 | 20.10 | 26.17 | 31.91 | 30.28 | 33.87 | 38.71 | 47.01 | 50.96 | ||||||||||
| PBIT | 82.35 | 82.14 | 145.43 | 138.67 | 142.26 | 153.34 | 230.93 | 93.42 | 101.51 | 117.08 | ||||||||||
| Interest & Other Items | 0.55 | 0.46 | 0.44 | 0.61 | 1.85 | 0.87 | 3.21 | 4.83 | 5.53 | 3.94 | ||||||||||
| PBT | 81.80 | 81.68 | 144.99 | 138.06 | 140.41 | 152.47 | 227.72 | 88.59 | 95.98 | 113.14 | ||||||||||
| Taxes & Other Items | 30.00 | 38.83 | 51.71 | 52.92 | 52.01 | 39.32 | 51.58 | 24.10 | 25.22 | 29.17 | ||||||||||
| Net Income | 51.80 | 42.85 | 93.28 | 85.14 | 88.40 | 113.15 | 176.14 | 64.49 | 70.76 | 83.97 | ||||||||||
| EPS | 9.94 | 7.98 | 17.36 | 15.99 | 16.74 | 21.41 | 33.30 | 12.19 | 13.37 | 15.86 | ||||||||||
| DPS | 10.00 | 10.00 | 10.00 | 20.00 | 5.00 | 25.00 | 15.00 | 18.00 | 0.00 | 18.00 | ||||||||||
| Payout ratio | 1.01 | 1.25 | 0.58 | 1.25 | 0.30 | 1.17 | 0.45 | 1.48 | 0.00 | 1.14 |
Company Updates
Peers & Comparison
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Thyrocare Technologies Ltd | 71.58 | 9.60 | — |
| Apollo Hospitals Enterprise Ltd | 110.97 | 13.62 | 0.23% |
| Max Healthcare Institute Ltd | 91.91 | 11.56 | 0.15% |
| Fortis Healthcare Ltd | 86.46 | 6.05 | 0.15% |
Price Comparison
Compare THYROCARE with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
High Pledged Promoter Holding
A significant proportion of promoter holdings is pledged
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Thyrocare Technologies Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Nippon India Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 3.6388% | Percentage of the fund’s portfolio invested in the stock 0.30% | Change in the portfolio weight of the stock over the last 3 months 0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 160/232 (-13) |
Nippon India Pharma Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 3.2605% | Percentage of the fund’s portfolio invested in the stock 1.90% | Change in the portfolio weight of the stock over the last 3 months 0.13% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 19/36 (+3) |
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.9435% | Percentage of the fund’s portfolio invested in the stock 0.37% | Change in the portfolio weight of the stock over the last 3 months 0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 30/94 (-6) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 16, 2024
Dividend/Share
₹18.00
Ex DateEx Date
Aug 16, 2024
Cash Dividend
Ex DateEx DateApr 20, 2023
Dividend/Share
₹18.00
Ex DateEx Date
Apr 20, 2023
Cash Dividend
Ex DateEx DateMay 11, 2022
Dividend/Share
₹15.00
Ex DateEx Date
May 11, 2022
Cash Dividend
Ex DateEx DateJun 17, 2021
Dividend/Share
₹15.00
Ex DateEx Date
Jun 17, 2021
Cash Dividend
Ex DateEx DateNov 12, 2020
Dividend/Share
₹10.00
Ex DateEx Date
Nov 12, 2020
Revenue from operations grew by 19.99% year on year (YoY) to Rs 177.36 crore in the quarter ended 30 September 2024. Profit before tax in Q2 FY25 stood at Rs 36.78 crore, up 30.10% as against Rs 28.27 crore posted in same quarter last year. Total expenses rose 16.88% YoY to Rs 142.90 crore during the quarter. Cost of materials and services consumed was at Rs 50.12 crore (up 16.34% YoY) while employee benefits expense stood at Rs 29.49 crore (up 8.98%) during the period under review. The company's revenue from Diagnostic Testing Services was at Rs 161.92 crore (up 18.40% YoY) while revenue from Imaging Services stood at Rs 14.15 crore (up 20.83% YoY) in Q1 FY25. EBITDA improved 28% YoY to Rs 48.2 crore in September 2024 quarter from Rs 37.6 crore reported in corresponding period previous year. EBITDA margin increased to 27% in Q2 FY25 as compared to 25% reported in the corresponding quarter last fiscal. On half year basis, the company's net profit jumped 35.06% to Rs 50.84 crore on 18.16% rise in revenue to Rs 334.27 crore in H1 FY25 over H1 FY24. Thyrocare Technologies is engaged in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India. The counter has hit a 52-week high at Rs 957.95 in today's intra-day session.Powered by Capital Market - Live
Net profit of Thyrocare Technologies rose 31.12% to Rs 26.67 crore in the quarter ended September 2024 as against Rs 20.34 crore during the previous quarter ended September 2023. Sales rose 19.84% to Rs 177.36 crore in the quarter ended September 2024 as against Rs 148.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales177.36148.00 20 OPM %27.0625.35 - PBDT49.8538.92 28 PBT36.7828.27 30 NP26.6720.34 31 Powered by Capital Market - Live
Thyrocare Technologies will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live
Thyrocare Technologies announced the cessation of Neetin Shivajirao Desai (DIN No: 02622364) as Independent Director of the company with effect from 19 September 2024 on completion of second term. Powered by Capital Market - Live
Thyrocare Technologies said that it shall have access to 11 centres of Vimta Labs at the locations such as Telangana, Andhra Pradesh, Uttar Pradesh and Odisha. The central processing laboratory, which is also a National Accreditation Board for Testing and Calibration Laboratories (NABL) accredited laboratory, is situated in Hyderabad, it added. Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs 30 crore during FY 2024 and Rs 7 Crore in Q1 FY 2025. The company added that the completion of the acquisition is subject to fulfilment of the conditions precedent. Rahul Guha, MD & CEO, Thyrocare Technologies, said, 'This strategic move aligns with our growth objectives, allowing Thyrocare to expand its market share, solidify our leadership position in South India, and grow our business with franchisees and hospitals. Additionally, this expansion will enable Thyrocare to leverage the benefits of scale.' Thyrocare Technologies is engaged in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India. Vimta Labs is a leading contract research and testing services provider in India. Shares of Thyrocare Technologies shed 0.10% to Rs 864.05 while those of Vimta Labs slipped 2.24% to Rs 627.55 on the BSE. Powered by Capital Market - Live
Thyrocare Technologies has signed a Business Transfer Agreement for purchase of the diagnostic and pathological services business of Vimta Labs. Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs 30 crore during FY 2024 and Rs 7 crore in Q1 FY 2025.Powered by Capital Market - Live
Thyrocare Technologies announced that the Annual General Meeting (AGM) of the company will be held on 23 August 2024.Powered by Capital Market - Live
Thyrocare expands Northern India presence with Polo Labs acquisition
Thyrocare Q1 Results Review - Margin Thesis Is Starting To Unfold: ICICI Securities
Gainers & Losers: Dabur, Avanti Feeds among 9 stocks in limelight on Wednesday
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 7.06%, vs industry avg of 10.02%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.13% to 0.94%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -3.63%, vs industry avg of 42.9%